HARBINGERHX Trademark

Trademark Overview

On Wednesday, November 29, 2023, a trademark application was filed for HARBINGERHX with the United States Patent and Trademark Office. The USPTO has given the HARBINGERHX trademark a serial number of 98290220. The federal status of this trademark filing is NON-FINAL ACTION - MAILED as of Friday, June 28, 2024. This trademark is owned by Harbinger Health, Inc.. The HARBINGERHX trademark is filed in the Pharmaceutical Products category with the following description:

Pharmaceuticals for use in the treatment and diagnosis of cancer; therapeutic pharmaceuticals for use in the treatment and diagnosis of cancer; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids and tissue samples for the treatment and diagnosis of cancer; pharmaceutical preparations comprised of medical diagnostic reagents and assays for testing of bodily fluids and tissue samples for the treatment and diagnosis of cancer: Scientific research, pharmaceutical research, medical research; technical scientific consultation and product development for others in the field of biotechnology and development of pharmaceuticals; platform as a service (PAAS) featuring computer software platforms for research and development in the field of computational biology, bioinformatics, genomics, biotechnology, and pharmaceuticals; drug discovery platform
harbingerhx

General Information

Serial Number98290220
Word MarkHARBINGERHX
Filing DateWednesday, November 29, 2023
Status641 - NON-FINAL ACTION - MAILED
Status DateFriday, June 28, 2024
Registration Number0000000
Registration DateNOT AVAILABLE
Mark Drawing4 - Illustration: Drawing with word(s) / letter(s) / number(s) in Block form
Published for Opposition DateNOT AVAILABLE

Trademark Statements

Goods and ServicesPharmaceuticals for use in the treatment and diagnosis of cancer; therapeutic pharmaceuticals for use in the treatment and diagnosis of cancer; diagnostic kits comprised of medical diagnostic reagents and assays for testing of bodily fluids and tissue samples for the treatment and diagnosis of cancer; pharmaceutical preparations comprised of medical diagnostic reagents and assays for testing of bodily fluids and tissue samples for the treatment and diagnosis of cancer: Scientific research, pharmaceutical research, medical research; technical scientific consultation and product development for others in the field of biotechnology and development of pharmaceuticals; platform as a service (PAAS) featuring computer software platforms for research and development in the field of computational biology, bioinformatics, genomics, biotechnology, and pharmaceuticals; drug discovery platform

Classification Information

International Class005 - Pharmaceutical and veterinary preparations; sanitary preparations for medical purposes; dietetic substances adapted for medical use, food for babies; plasters, materials for dressings; material for stopping teeth, dental wax; disinfectants; preparations for destroying vermin; fungicides, herbicides.
US Class Codes005, 006, 018, 044, 046, 051, 052
Class Status Code6 - Active
Class Status DateTuesday, November 28, 2023
Primary Code005
First Use Anywhere DateNOT AVAILABLE
First Use In Commerce DateNOT AVAILABLE

Trademark Owner History

Party NameHarbinger Health, Inc.
Party Type10 - Original Applicant
Legal Entity Type03 - Corporation
AddressCAMBRIDGE, MA 02138

Trademark Events

Event DateEvent Description
Thursday, November 30, 2023NEW APPLICATION ENTERED
Friday, February 16, 2024NEW APPLICATION OFFICE SUPPLIED DATA ENTERED
Friday, June 28, 2024NON-FINAL ACTION E-MAILED
Thursday, February 29, 2024TEAS CHANGE OF OWNER ADDRESS RECEIVED
Thursday, February 29, 2024APPLICANT/CORRESPONDENCE CHANGES (NON-RESPONSIVE) ENTERED
Thursday, February 29, 2024TEAS CHANGE OF CORRESPONDENCE RECEIVED
Thursday, June 27, 2024ASSIGNED TO EXAMINER
Friday, June 28, 2024NON-FINAL ACTION WRITTEN
Friday, July 19, 2024APPLICATION EXTENSION GRANTED/RECEIPT PROVIDED
Friday, July 19, 2024APPLICATION EXTENSION TO RESPONSE PERIOD - RECEIVED
Friday, June 28, 2024NOTIFICATION OF NON-FINAL ACTION E-MAILED

Related Keywords

harbingerhx pharmaceuticals cancer research diagnosis treatment development medical diagnostic scientific samples